Sodium acid phosphate 700mg / Potassium dihydrogen phosphate 305mg tablets
Available from pharmacies, supermarkets, and retail outlets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Sodium acid phosphate + Potassium dihydrogen phosphate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 4 · 2016–2026
Showing the 50 most relevant studies, sorted by most relevant.
Seema Gosavi, Rushikesh Nanaware
Asian Journal of Pharmaceutical Analysis, 2024
Hegde NN, Somanatha H, Lakshmi V C, et al.
2026
Tsai P, Maalouf NM
2026
In this article, we review the recent epidemiology, unique pathophysiology, and challenges in medical management of calcium phosphate (CaP) kidney stones. CaP stones represent the second most encountered stone type. Compared with the more common calcium oxalate stones, CaP stones are more likely to occur in women, have increased in prevalence in recent decades, and recur at a higher rate. Stone formers presenting with hydroxyapatite and brushite stones, the 2 most common subtypes of CaP stones, exhibit distinct histopathologic findings. Urinary risk factors contributing to CaP stone formation include high urine pH, hypercalciuria, and hypocitraturia. These changes in the urinary environment occur from a variety of inherited or acquired conditions. The current approach to medical management of CaP stones is primarily extrapolated from studies performed in calcium oxalate stone formers, and the role of alkali therapy in CaP stone formers is controversial. Therefore, there is a critical need for treatments tailored to address the high recurrence rate, distinct pathophysiology, and risk factors of CaP nephrolithiasis.
Abstract licence: CC BY-NC-ND
Yu W, Deng C, Chen S, et al.
2026
- Osteomalacia
- Osteoporosis
- Hypophosphatemia
The nephrotoxicity of adefovir dipivoxil (ADV) can induce Fanconi syndrome, which causes hypophosphatemic osteomalacia. We report a case of a 67-year-old postmenopausal woman who had been receiving long-term adefovir dipivoxil therapy for chronic hepatitis B. She presented with severe bone pain and multiple pseudofractures, and was diagnosed with drug-induced hypophosphatemic osteomalacia. Following discontinuation of adefovir and supplementation with vitamin D and phosphate, her biochemical parameters normalized and bone pain significantly improved, indicating that osteomalacia had been essentially corrected. However, although follow-up bone mineral density (BMD) showed significant improvement compared to pretreatment values, it remained markedly below the reference range for age-matched women. Postmenopausal osteoporosis was therefore suspected, and anti-osteoporotic pharmacotherapy was initiated after correction of osteomalacia. This case suggests that BMD can improve substantially after removal of the causative factor in drug-induced osteomalacia; however, if patients have underlying risk factors for osteoporosis, low BMD may persist even after osteomalacia resolution, necessitating further evaluation and intervention.
Abstract licence: CC BY
M. D. Kavitha, S. Kathiresan, S. Bhattacharya, et al.
Journal of Food Science and Technology, 2016
Qinglong Huang, Su-Su Wang, Yongsheng Du, et al.
Materials, 2024
Yang L, Layton CL, Goult CA, et al.
2026
Per- and polyfluoroalkyl substances (PFAS) are persistent environmental pollutants, some associated with detrimental impacts on human health upon chronic exposure. Many processes have been reported to destroy PFAS, although high-temperature thermal methods such as incineration or pyrolysis are still the most commonly used for bulk waste. Herein, we report a highly effective mechanochemical process designed to destroy polymeric and nonpolymeric PFAS with recovery of fluorine as NaF, a salt endorsed by international organizations for public oral health. The process consists of ball milling PFAS with commercially available sodium silicate, an inexpensive and easy-to-handle reagent found to be superior to sodium phosphate or carbonate. This approach represents a promising step toward remediating the global PFAS crisis with a circular fluorine economy in mind.
Abstract licence: CC BY
M. A. Shaymardanova, K. Mirzakulov, G. Melikulova, et al.
Chemical Problems, 2023
Xiaobo Zou, Lixiu Yan, Xiaofang Luo, et al.
MATEC Web of Conferences, 2023
Byrd EJ, Norgate EL, Crossley JA, et al.
2026
- Spectrometry, Mass, Electrospray Ionization
- Nanotechnology
- alpha-Synuclein
Buffer and electrolyte conditions in vivo and in vitro are known to influence protein structure and function. Intrinsically disordered proteins (IDPs) are particularly sensitive to their solution conditions such as ionic strength and molecular crowding, and their dynamic structural ensembles rapidly respond to the cellular environment. While structural mass spectrometry (MS) techniques are uniquely able to capture aspects of this structural diversity, technical limitations have largely precluded the use of native MS and ion mobility (IM) to interrogate the conformations of IDPs in the presence of different buffers and biologically relevant concentrations of nonvolatile salts. Here, we overcome this challenge by employing sub-100 nm nanopipette electrospray ionization emitters that enable gentle and salt-tolerant analysis to study the conformational distribution of α-Synuclein (αS) monomers using native IM-MS in varied solution conditions, including in phosphate-buffered saline. We show using native MS that it is possible to capture salt- and buffer-induced changes in the αS conformational ensemble in commonly used biochemical buffers, which reflect structural changes from in silico predictions and in-solution measurements. This work demonstrates the power of nanopipette emitters for the study of IDPs and establishes native MS as a method that can be routinely used to study the conformational landscape of IDPs in nonvolatile and biologically relevant buffers.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.